Hybrigenics unveils final results of inecalcitol Phase IIa clinical study in hormone-refractory prostate cancer
Widening its clinical application to hormone-dependent prostate cancer, hyperparathyroidism, and severe psoriasis
21-Sep-2010 -
Hybrigenics announced the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients. The maximal tolerated dose of inecalcitol is 4 milligrams (mg) per day and the ...
calcium
chemotherapy
chronic renal disease
+5